On Friday, Standard BioTools Inc (NASDAQ: LAB) was 5.56% up from the session before settling in for the closing price of $1.80. A 52-week range for LAB has been $1.21 – $3.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -0.06%. When this article was written, the company’s average yearly earnings per share was at 56.74%. With a float of $359.12 million, this company’s outstanding shares have now reached $371.15 million.
Let’s determine the extent of company efficiency that accounts for 539 employees. In terms of profitability, gross margin is 46.67%, operating margin of -85.69%, and the pretax margin is -87.0%.
Standard BioTools Inc (LAB) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Standard BioTools Inc stocks. The insider ownership of Standard BioTools Inc is 3.24%, while institutional ownership is 72.52%. The most recent insider transaction that took place on Sep 09 ’24, was worth 91,725. Before that another transaction happened on Aug 27 ’24, when Company’s Director bought 250,000 for $2.19, making the entire transaction worth $546,750. This insider now owns 54,025,821 shares in total.
Standard BioTools Inc (LAB) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.27 earnings per share (EPS) during the time that was less than consensus figure (set at -0.12) by -0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 56.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.06% during the next five years compared to 8.72% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
You can see what Standard BioTools Inc (LAB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.90, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.21 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Looking closely at Standard BioTools Inc (NASDAQ: LAB), its last 5-days average volume was 0.92 million, which is a drop from its year-to-date volume of 2.46 million. As of the previous 9 days, the stock’s Stochastic %D was 75.36%. Additionally, its Average True Range was 0.10.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 48.08%, which indicates a significant decrease from 91.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.08% in the past 14 days, which was lower than the 100.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9146, while its 200-day Moving Average is $2.2406. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.9400. Second resistance stands at $1.9800. The third major resistance level sits at $2.0550. If the price goes on to break the first support level at $1.8250, it is likely to go to the next support level at $1.7500. Should the price break the second support level, the third support level stands at $1.7100.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
There are 370,421K outstanding shares of the company, which has a market capitalization of 705.18 million. As of now, sales total 106,340 K while income totals -74,660 K. Its latest quarter income was 37,210 K while its last quarter net income were -45,720 K.
